TNSN02038A1 - Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant - Google Patents

Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant

Info

Publication number
TNSN02038A1
TNSN02038A1 TNTNSN02038A TNSN02038A TNSN02038A1 TN SN02038 A1 TNSN02038 A1 TN SN02038A1 TN TNSN02038 A TNTNSN02038 A TN TNSN02038A TN SN02038 A TNSN02038 A TN SN02038A TN SN02038 A1 TNSN02038 A1 TN SN02038A1
Authority
TN
Tunisia
Prior art keywords
pregabalin
compositions containing
new
conjugated compounds
lactose
Prior art date
Application number
TNTNSN02038A
Other languages
English (en)
Inventor
Robert Hurley Timothy
James Lovdahl Michael
Tobias Brian
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TNSN02038A1 publication Critical patent/TNSN02038A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION A POUR OBJET DES COMPOSES CONJUGUES DE PREGABALINE ET DE LACTOSE. ELLE CONCERNE EGALEMENT DES COMPOSITIONS LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT DE DIVERSES MALADIES DU SYSTEME NERVEUX CENTRAL.
TNTNSN02038A 2001-03-30 2002-03-29 Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant TNSN02038A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
TNSN02038A1 true TNSN02038A1 (fr) 2005-12-23

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN02038A TNSN02038A1 (fr) 2001-03-30 2002-03-29 Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant

Country Status (32)

Country Link
US (1) US7022678B2 (fr)
EP (1) EP1377318A2 (fr)
JP (1) JP2004524357A (fr)
KR (1) KR20040008146A (fr)
CN (1) CN1511043A (fr)
AP (1) AP2003002873A0 (fr)
AR (1) AR033024A1 (fr)
BG (1) BG108193A (fr)
BR (1) BR0208439A (fr)
CA (1) CA2440468C (fr)
CZ (1) CZ20032547A3 (fr)
DO (1) DOP2002000356A (fr)
EA (1) EA200300954A1 (fr)
EC (1) ECSP034740A (fr)
EE (1) EE200300480A (fr)
GT (1) GT200200051A (fr)
HU (1) HUP0303956A2 (fr)
IL (1) IL157879A0 (fr)
IS (1) IS6912A (fr)
MA (1) MA27004A1 (fr)
MX (1) MXPA03007437A (fr)
NO (1) NO20034348L (fr)
OA (1) OA12456A (fr)
PA (1) PA8542101A1 (fr)
PE (1) PE20021016A1 (fr)
PL (1) PL369179A1 (fr)
SK (1) SK11832003A3 (fr)
SV (1) SV2003000928A (fr)
TN (1) TNSN02038A1 (fr)
UY (1) UY27233A1 (fr)
WO (1) WO2002078747A2 (fr)
ZA (1) ZA200306608B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US7446220B2 (en) * 2005-09-19 2008-11-04 Teva Pharmaceutical Industries Ltd. Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2297090A1 (fr) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Synthèse enzymatique stéréosélective de l ester (s) ou (r)-isobutylglutarique
WO2010115612A2 (fr) 2009-04-10 2010-10-14 Synthon B.V. Compositions de prégabaline
WO2010150221A1 (fr) 2009-06-25 2010-12-29 Wockhardt Research Centre Compositions pharmaceutiques de prégabaline de saveur masquée
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
ES2279631T3 (es) * 1998-10-16 2007-08-16 Warner-Lambert Company Llc Uso de analogos de gaba para la fabricaion de un medicamento para el tratamiento de mania y trastornos bipolares.
AU2002215159A1 (en) * 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of GABA agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
NO20034348D0 (no) 2003-09-29
WO2002078747A2 (fr) 2002-10-10
EP1377318A2 (fr) 2004-01-07
BG108193A (en) 2004-09-30
SV2003000928A (es) 2003-07-29
WO2002078747A9 (fr) 2003-12-31
ZA200306608B (en) 2004-11-25
CZ20032547A3 (en) 2004-04-14
GT200200051A (es) 2002-11-15
OA12456A (en) 2004-08-24
NO20034348L (no) 2003-09-29
WO2002078747A8 (fr) 2003-12-04
BR0208439A (pt) 2004-03-23
MXPA03007437A (es) 2003-11-18
EE200300480A (et) 2003-12-15
US7022678B2 (en) 2006-04-04
SK11832003A3 (sk) 2004-04-06
CA2440468C (fr) 2008-09-02
DOP2002000356A (es) 2002-12-15
MA27004A1 (fr) 2004-12-20
CA2440468A1 (fr) 2002-10-10
PL369179A1 (en) 2005-04-18
UY27233A1 (es) 2002-10-31
AR033024A1 (es) 2003-12-03
HUP0303956A2 (hu) 2004-04-28
PA8542101A1 (es) 2002-10-28
US20020187941A1 (en) 2002-12-12
KR20040008146A (ko) 2004-01-28
WO2002078747A3 (fr) 2003-10-09
EA200300954A1 (ru) 2004-02-26
CN1511043A (zh) 2004-07-07
IL157879A0 (en) 2004-03-28
ECSP034740A (es) 2003-12-24
IS6912A (is) 2003-08-14
JP2004524357A (ja) 2004-08-12
PE20021016A1 (es) 2002-11-14
AP2003002873A0 (en) 2003-09-30

Similar Documents

Publication Publication Date Title
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
TNSN98022A1 (fr) DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
TNSN97122A1 (fr) Inhibiteurs des metalloproteinases de matrice a base de phosphinates
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
WO2002002506A8 (fr) Composes pour traiter la maladie d'alzheimer
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01150A1 (fr) Pyrimidine-2,4,6- triones inhibitrices de metalloproteinases, et compositions les contenant.
AU2001252958A1 (en) Compounds and methods to treat alzheimer's disease
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
MY136707A (en) Thrombopoietin mimetics
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
ZA9810444B (en) Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
BR0213358A (pt) Uso de flibanserina
WO2002002520A8 (fr) Composants utilises dans le traitement de la maladie d'alzheimer
GB0108592D0 (en) Therapeutic agents